FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes
E. de Poel, S. Spelier, M. C. Hagemeijer, P. van Mourik, S. W. F. Suen, A. M. Vonk, J. E. Brunsveld, G. N. Ithakisiou, E. Kruisselbrink, H. Oppelaar, G. Berkers, K. M. de Winter de Groot, S. Heida-Michel, S. R. Jans, H. van Panhuis, M. Bakker, R. van der Meer, J. Roukema, E. Dompeling, E. J. M. WeersinkG. H. Koppelman, A. R. Blaazer, J. E. Muijlwijk-Koezen, C. K. van der Ent, J. M. Beekman*
Research output: Contribution to journal › Article › Academic › peer-review
Fingerprint
Dive into the research topics of 'FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes'. Together they form a unique fingerprint.